S Ehrlich1, A Yendiki1, D N Greve1, D S Manoach1, B-C Ho2, T White3, S C Schulz3, D C Goff4, R L Gollub1, D J Holt1. 1. MGH/MIT/HMS Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, USA. 2. Department of Psychiatry, University of Iowa, Iowa City, IA, USA. 3. Department of Psychiatry and the Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, USA. 4. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Abstract
BACKGROUND: Previous studies have suggested that motivational aspects of executive functioning, which may be disrupted in schizophrenia patients with negative symptoms, are mediated in part by the striatum. Negative symptoms have been linked to impaired recruitment of both the striatum and the dorsolateral prefrontal cortex (DLPFC). Here we tested the hypothesis that negative symptoms are associated primarily with striatal dysfunction, using functional magnetic resonance imaging (fMRI). METHOD: Working-memory load-dependent activation and gray matter volumes of the striatum and DLPFC were measured using a region-of-interest (ROI) approach, in 147 schizophrenia patients and 160 healthy controls. In addition to testing for a linear relationships between striatal function and negative symptoms, we chose a second, categorical analytic strategy in which we compared three demographically and behaviorally matched subgroups: patients with a high burden of negative symptoms, patients with minimal negative symptoms, and healthy subjects. RESULTS: There were no differences in striatal response magnitudes between schizophrenia patients and healthy controls, but right DLPFC activity was higher in patients than in controls. Negative symptoms were inversely associated with striatal, but not DLPFC, activity. In addition, patients with a high burden of negative symptoms exhibited significantly lower bilateral striatal, but not DLPFC, activation than schizophrenia patients with minimal negative symptoms. Working memory performance, antipsychotic exposure and changes in gray matter volumes did not account for these differences. CONCLUSIONS: These data provide further evidence for a robust association between negative symptoms and diminished striatal activity. Future work will determine whether low striatal activity in schizophrenia patients could serve as a reliable biomarker for negative symptoms.
BACKGROUND: Previous studies have suggested that motivational aspects of executive functioning, which may be disrupted in schizophreniapatients with negative symptoms, are mediated in part by the striatum. Negative symptoms have been linked to impaired recruitment of both the striatum and the dorsolateral prefrontal cortex (DLPFC). Here we tested the hypothesis that negative symptoms are associated primarily with striatal dysfunction, using functional magnetic resonance imaging (fMRI). METHOD: Working-memory load-dependent activation and gray matter volumes of the striatum and DLPFC were measured using a region-of-interest (ROI) approach, in 147 schizophreniapatients and 160 healthy controls. In addition to testing for a linear relationships between striatal function and negative symptoms, we chose a second, categorical analytic strategy in which we compared three demographically and behaviorally matched subgroups: patients with a high burden of negative symptoms, patients with minimal negative symptoms, and healthy subjects. RESULTS: There were no differences in striatal response magnitudes between schizophreniapatients and healthy controls, but right DLPFC activity was higher in patients than in controls. Negative symptoms were inversely associated with striatal, but not DLPFC, activity. In addition, patients with a high burden of negative symptoms exhibited significantly lower bilateral striatal, but not DLPFC, activation than schizophreniapatients with minimal negative symptoms. Working memory performance, antipsychotic exposure and changes in gray matter volumes did not account for these differences. CONCLUSIONS: These data provide further evidence for a robust association between negative symptoms and diminished striatal activity. Future work will determine whether low striatal activity in schizophreniapatients could serve as a reliable biomarker for negative symptoms.
Authors: Kelly Rowe Bijanki; Brendan Hodis; Vincent A Magnotta; Eugene Zeien; Nancy C Andreasen Journal: Schizophr Res Date: 2014-06-20 Impact factor: 4.939
Authors: Matthias Kirschner; Oliver M Hager; Martin Bischof; Matthias N Hartmann; Agne Kluge; Erich Seifritz; Philippe N Tobler; Stefan Kaiser Journal: J Psychiatry Neurosci Date: 2016-04 Impact factor: 6.186
Authors: Kristin K Lottman; David M White; Nina V Kraguljac; Meredith A Reid; Vince D Calhoun; Fabio Catao; Adrienne C Lahti Journal: Hum Brain Mapp Date: 2018-01-09 Impact factor: 5.038
Authors: Victor Peralta; Lucía Moreno-Izco; Ana Sanchez-Torres; Elena García de Jalón; Maria S Campos; Manuel J Cuesta Journal: Schizophr Bull Date: 2012-12-18 Impact factor: 9.306
Authors: James A Waltz; Ziye Xu; Elliot C Brown; Rebecca R Ruiz; Michael J Frank; James M Gold Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2017-08-12
Authors: Jaime K Brown; James A Waltz; Gregory P Strauss; Robert P McMahon; Michael J Frank; James M Gold Journal: Psychiatry Res Date: 2013-05-09 Impact factor: 3.222
Authors: Daniel Geisler; Esther Walton; Melissa Naylor; Veit Roessner; Kelvin O Lim; S Charles Schulz; Randy L Gollub; Vince D Calhoun; Scott R Sponheim; Stefan Ehrlich Journal: Psychiatry Res Date: 2015-08-21 Impact factor: 3.222
Authors: Esther Walton; Daniel Geisler; Phil H Lee; Johanna Hass; Jessica A Turner; Jingyu Liu; Scott R Sponheim; Tonya White; Thomas H Wassink; Veit Roessner; Randy L Gollub; Vince D Calhoun; Stefan Ehrlich Journal: Schizophr Bull Date: 2013-12-10 Impact factor: 9.306